ClinicalTrials.gg
Not yet recruitingNCT07732231ASPIRUpdated Jul 28, 2026

Cost-utility Analysis of Outpatient Manual Vacuum Aspiration Versus Operating Room Electric Aspiration for the Management of First-trimester Miscarriage

An interventional study of Manual vacuum aspiration (MVA) and Electric aspiration (EA) in Miscarriage, Pregnancy Loss and First Trimester Pregnancy, sponsored by Nantes University Hospital. Not yet recruiting at 1 site in France. Open to female participants aged 18 Years to 44 Years. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Nantes University Hospital · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
860
Allocation
Randomized
Ages
18 Years to 44 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 27 studies in Abortion, Spontaneous with a site in France — 7 open to participants now, 8 under way, none of them phase 3. Abortion, Spontaneous · France.

Planned enrollment
2nd of 14
860 · median 210
Started
2026
with 1 other
No phase
12 of 27
5 open now
Registered
26th of 27
by date

Among the 27 studies in Abortion, Spontaneous with a site in France, this one is the 2nd largest by planned enrollment of the 14 interventional ones, is one of 2 that started in 2026, is one of 12 with no phase, and was the 26th registered.

By phase

27 studies; the count open now beside each. This study's row is marked.

Observational13 · 2 open
No phasethis study12 · 5 open
Phase 1/21 · 0 open
Phase 31 · 0 open

By the year they started

First in 2012; this study’s year is marked. 2 started in 2026.

What they test

Size and results

Median enrollment 210 across the 14 interventional studies, 202 across the 13 observational. Of the 15 that completed or were terminated, 0 (0%) have results posted.

Was this useful?
Watch this landscapeDownload CSVWith an account: a weekly mail of what changed among 27 studies in Abortion, Spontaneous with a site in France, or all of them as a file.
02

Study summary

The ASPIR study aims to evaluate the cost-utility of outpatient manual vacuum aspiration compared with operating room electric aspiration for the management of first-trimester miscarriage. It is hypothesized that manual aspiration will demonstrate equivalent clinical efficacy and patient quality of life while reducing healthcare costs.

Read the detailed description

Miscarriage occurs in approximately 15% of pregnancies during the first trimester. In France, surgical management usually involves electric aspiration in the operating room under anesthesia, associated with hospital admission. Manual vacuum aspiration (MVA) is widely used in low-resource settings and for induced abortion, with demonstrated safety and patient satisfaction. This multicenter randomized controlled trial compares outpatient MVA under local anesthesia and inhaled analgesia versus electric aspiration (EA) under anesthesia in the operating room.

The primary objective is to assess the incremental cost-utility ratio (ICUR, cost per QALY) at 3 months. Secondary outcomes include complications, pain, satisfaction, quality of life, and fertility at 12 months. The study anticipates enrolling 860 participants across multiple centers in France.

03

Conditions studied

  • Miscarriage
  • Pregnancy Loss
  • First Trimester Pregnancy

Browse trials for

Keywords

  • Manual vacuum aspiration
  • Electric aspiration
  • Cost-effectiveness
  • Health economics
  • Gynecology
  • Pregnancy loss
  • miscarriage
04

Who can participate

Ages eligible
18 Years to 44 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female, aged 18-44 years
  • Ultrasound-confirmed first-trimester miscarriage requiring surgical management
  • Gestational age between 5 and 12 weeks of amenorrhea
  • Incomplete spontaneous abortion or ongoing non-viable pregnancy
  • Patient able to provide oral

Exclusion criteria

Exclusion Criteria:

  • Complete expulsion of pregnancy (endometrial thickness \< 15 mm)
  • Choice of medical treatment with misoprostol
  • Elective termination of pregnancy
  • Unwanted pregnancy
  • Pregnancy of unknown location, molar pregnancy
  • Known uterine malformation
  • Prior surgical aspiration for the current pregnancy
  • Intrauterine device in place
  • Contraindicating medications (e.g. anticoagulants)
  • Protected adults (under guardianship)
  • Inability to complete study questionnaires
  • Lack of social security coverage
  • Haemorrhagic miscarriage
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
860 participants (estimated)

Study arms

  • Experimental
    Manual vacuum aspiration (MVA)

    Outpatient manual vacuum aspiration under local anesthesia and inhaled analgesia (MEOPA).

    Procedure: Manual vacuum aspiration (MVA)

  • Active comparator
    Electric aspiration in the operating room under general or regional anesthesia. Electric aspiration

    Electric aspiration in the operating room under general or regional anesthesia. Performed in the operating room under general or regional anesthesia, using an electric suction device and appropriate cannula. Post-procedure pelvic ultrasound to confirm complete evacuation.

    Procedure: Electric aspiration (EA)

Interventions

  • ProcedureManual vacuum aspiration (MVA)

    Performed in consultation under local anesthesia and inhaled analgesia, using a manual vacuum aspirator and appropriate cannula. Post-procedure pelvic ultrasound to confirm complete evacuation.

  • ProcedureElectric aspiration (EA)

    Performed in the operating room under general or regional anesthesia, using an electric suction device and appropriate cannula. Post-procedure pelvic ultrasound to confirm complete evacuation.

06

What researchers measure

Primary outcomes

  1. Incremental cost-utility ratio (ICUR)

    Incremental cost per quality-adjusted life year (QALY) gained of outpatient MVA compared to operating room EA, from a collective perspective.

    Time frame: 3 months

Secondary outcomes

  1. Annual net financial benefit for health insurance over up to 5 years of different development scenarios for manual vacuum aspiration in consultation for the management of pregnancies terminated before 12 weeks of gestation

    Annual net financial benefit for health insurance over up to 5 years of different development scenarios for manual vacuum aspiration in consultation for the management of pregnancies terminated before 12 weeks of gestation

    Time frame: up to 5 years

  2. To compare the two management strategies in terms of success and intraoperative and postoperative complications

    To compare the two management strategies in terms of success and intraoperative and postoperative complications * 2.1 Management failure defined by the need for second-line treatment (aspiration, misoprostol, etc.) * 2.2 Intraoperative complications: change of strategy, bleeding greater than 200 ml, uterine perforation, etc., and all possible complications classified according to the Clavien and Dindo criteria * 2.3 Trophoblastic retention image defined by retention (heterogeneous intrauterine mass independent of the endometrium) greater than 20 mm thick on transvaginal ultrasound at M1.

    Time frame: 1 month

  3. To assess patient satisfaction

    To assess patient satisfaction: A numerical scale (NS) (0-10) on Days 1 and 2.

    Time frame: day 1 and 2

  4. To compare the two strategies (electric suction versus manual vacuum kit suction)

    To compare the two strategies (electric suction versus manual vacuum kit suction), measurement of: ●Pain via NS (a scale from 0 to 10) on Day 0 (before the procedure, 30 min after the procedure +/- 30 min), Days 1, 7, 1, and 3

    Time frame: days 0, 1,7 and 1 and 3 months

  5. The risk factors for failure

    The risk factors for failure at M3 studied will be: the term of the terminated pregnancy, patient compliance, patient satisfaction (numerical scale (from 0 to 10), patient characteristics (age).

    Time frame: 3 months

  6. Satisfaction with the patient's care by medical staff

    Satisfaction with the patient's care by medical staff will be assessed using an EN (numerical scale 0 to 10) at D0 and M1

    Time frame: day 0 and 1 month

  7. Patient having been pregnant in days

    Patient having been pregnant at 12 months, pregnancy outcome and time to conception in days.

    Time frame: 12 months

  8. To assess patient satisfaction

    To assess patient satisfaction: A numerical scale (NS) (0-10) on Days 1 and 2. HADS (Hospital Anxiety and Depression Scale) and PCL-5 questionnaires at 1 and 3 months

    Time frame: day 1 and 2 and 1 month et 3 month

  9. To assess patient satisfaction

    HADS (Hospital Anxiety and Depression Scale) and PCL-5 questionnaires at 1 and 3 months

    Time frame: 1 and 3 months

  10. To compare the two strategies (electric suction versus manual vacuum kit suction)

    To compare the two strategies (electric suction versus manual vacuum kit suction), measurement of: ●Pain via NS (a scale from 0 to 10) on Day 0 (before the procedure, 30 min after the procedure +/- 30 min), Days 1, 7, 1, and 3

    Time frame: Day 0, 1,7 and 1 and 3 months

  11. To compare the two strategies (electric suction versus manual vacuum kit suction)

    To compare the two strategies (electric suction versus manual vacuum kit suction), measurement of: ●Analgesic consumption (type, quantity, and duration) from Day 0 to 7

    Time frame: Day 0 to 7

  12. To compare the two strategies (electric suction versus manual vacuum kit suction)

    To compare the two strategies (electric suction versus manual vacuum kit suction), measurement of: ●Number of pads used per day (Higham score) from Days 1 to 7

    Time frame: Day 0 to 7

  13. To compare the two strategies (electric suction versus manual vacuum kit suction)

    To compare the two strategies (electric suction versus manual vacuum kit suction), measurement of: * Duration of the procedure in minutes * Waiting time for therapeutic treatment in minutes * Time spent in hospital in minutes

    Time frame: Day 0

  14. To compare the two strategies (electric suction versus manual vacuum kit suction)

    To compare the two strategies (electric suction versus manual vacuum kit suction) ● Postoperative complications will include:Perioperative bleeding greater than 200 ml (Higham score), infection (temperature \>38°C and pelvic symptoms) …classified according to the Calvien and Dindo criteria, at M1, the persistence of abnormal bleeding, trophoblastic retention, at M3, the presence of amenorrhea outside the context of a new pregnancy

    Time frame: 1 and 3 months

  15. To compare the two strategies (electric suction versus manual vacuum kit suction)

    To compare the two strategies (electric suction versus manual vacuum kit suction), measurement of: ●quality of life questionnaires EQ-5D-5L, PGI-I at M1 and M3

    Time frame: 1 et 3 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — Individual participant data may be shared upon reasonable request, subject to sponsor approval and compliance with French/EU data protection regulations (GDPR).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Jan 2027, 3 months later.

Of 43 non-industry interventional studies with no phase under Abortion, Spontaneous, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 3 months is below that.

Counting every sponsor, half of 45 studies reached it within 27 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2026
First posted
Jul 28, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Jan 1, 2027
CompletionEst.
Oct 1, 2029
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07732231
Responsible party
Sponsor
First posted
Jul 28, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Jan 1, 2027 (estimated)
Completion
Oct 1, 2029 (estimated)
Last update
Jul 28, 2026

Study contacts

Thibault Thubert, Pr
Contact
thibault.thubert@chu-nantes.fr
+33253482443
Thibault Thubert, Pr
principal investigator · Nantes University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion